Overview

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Status:
Active, not recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

West German Study Group

Treatments:

Albumin-Bound Paclitaxel
Cyclophosphamide
Docetaxel
Epirubicin
Paclitaxel
Taxane